Dawei Yuan
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Inflammatory Biomarkers in Disease Prognosis
Papers in
-
- RNA modifications and cancer 8
- Circular RNAs in diseases 6
- RNA Research and Splicing 3
- Microbial Metabolic Engineering and Bioproduction 3
-
- Cancer-related molecular mechanisms research 12
- MicroRNA in disease regulation 5
- Co-authors
- Kun Zhu (19 shared papers)Chengxue Dang (15 shared papers)Rong Yan (9 shared papers)Kang Li (7 shared papers)Patricia Relue (2 shared papers)Sasidhar Varanasi (2 shared papers)Kang Li (5 shared papers)Yong Jia (2 shared papers)
- Journals
- Oncotarget (3 papers)Frontiers in Oncology (2 papers)BioMed Research International (2 papers)Bioresource Technology (2 papers)Clinical & Translational Oncology (1 paper)
- Partner nations
- ChinaUnited StatesRussia
In The Last Decade
Dawei Yuan
47 papers receiving 741 citations
Peers
Comparison fields: 5 of 96
- Cancer Research 299
- Oncology 175
- Molecular Biology 431
- Pharmacology 43
- Otorhinolaryngology 17
Countries citing papers authored by Dawei Yuan
This map shows the geographic impact of Dawei Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawei Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawei Yuan more than expected).
Fields of papers citing papers by Dawei Yuan
This network shows the impact of papers produced by Dawei Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawei Yuan. The network helps show where Dawei Yuan may publish in the future.
Co-authors
The 25 scholars most cited alongside Dawei Yuan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 68 | |
| 2 | 2023 | 52 | |
| 3 | 2014 | 51 | |
| 4 | 2004 | 48 | |
| 5 | Stigmasterol exhibits potent antitumor effects in human gastric cancer cells mediated via inhibition of cell migration, cell cycle arrest, mitochondrial mediated apoptosis and inhibition of JAK/STAT signalling pathway. | 2019 | 47 |
| 6 | 2013 | 38 | |
| 7 | 2018 | 38 | |
| 8 | 2020 | 37 | |
| 9 | 2012 | 35 | |
| 10 | 2010 | 33 | |
| 11 | 2018 | 32 | |
| 12 | 2020 | 28 | |
| 13 | 2020 | 25 | |
| 14 | 2018 | 22 | |
| 15 | 2020 | 16 | |
| 16 | 2021 | 15 | |
| 17 | 2020 | 14 | |
| 18 | 2012 | 12 | |
| 19 | 2021 | 10 | |
| 20 | 2023 | 9 |
About Dawei Yuan
Dawei Yuan is a scholar working on Molecular Biology, Cancer Research, Oncology, Immunology and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 750 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (12 papers), RNA modifications and cancer (8 papers), Circular RNAs in diseases (6 papers), MicroRNA in disease regulation (5 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), RNA Research and Splicing (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Microbial Metabolic Engineering and Bioproduction (3 papers). The work is most often cited by research in Cancer Research (299 citations), Oncology (175 citations), Molecular Biology (431 citations), Pharmacology (43 citations) and Otorhinolaryngology (17 citations). Dawei Yuan has collaborated with scholars based in China, United States and Russia. Frequent co-authors include Kun Zhu, Chengxue Dang, Rong Yan, Kang Li, Patricia Relue, Sasidhar Varanasi, Kang Li, Yong Jia, Haonan Wang and Kang Li. Their work appears in journals such as Oncotarget, Frontiers in Oncology, BioMed Research International, Bioresource Technology and Clinical & Translational Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.